Why is larotrectinib not recommended?

Although larotrectinib (Larotrectinib) is a targeted anti-cancer drug that has shown significant efficacy in certain cases, not everyone is suitable or needs to use this drug. The following are some situations in which larotrectinib is not recommended:

1.Lack ofTRKgene fusion: Larotrectinib is mainly suitable for cancer patients with TRK (neuroprimitive ectodermal tumor) gene fusion. If a patient's genetic testing does not reveal the TRK gene fusion, larotrectinib may not be necessary because the drug may not be effective against other types of cancer.

2.Other treatment options exist: In some cases, other treatment options may exist, such as traditional chemotherapy, radiation therapy, or other targeted therapies. Doctors may choose the most appropriate treatment option based on the patient's specific circumstances and condition, and may not necessarily choose larotrectinib.

3.Potential side effects and safety issues: Although larotrectinib shows relatively good safety and tolerability, there are still some possible side effects, such as fatigue, headache, vomiting, etc. For some patients, especially those with other health problems, these side effects may adversely affect quality of life.

4.Cost issue: The cost of some new anti-cancer drugs is relatively high, which may have an impact on patients’ financial burden. When considering larotrectinib, patients and physicians need to weigh efficacy and cost together and ensure that they can afford or obtain appropriate health insurance coverage.

5.Children and pregnant women: The safety of larotrectinib has not been fully studied in children and pregnant women, so use in these two specific groups should be cautious. In these populations, more detailed studies and evaluations may be needed to ensure the drug's safety.

Larotrectinib has been launched in China and has not yet been included in medical insurance. Since it has not been launched in China for a long time, it may be difficult to purchase it in hospitals. For specific conditions, it is recommended to consult the local hospital pharmacy. In foreign markets, larotinib has two options: original drug and generic drug. Original drugs include the German version, the American version, the European version and the Hong Kong version, and the price is about 10,000 to 20,000 yuan. In comparison, generic drugs are much cheaper. There are Lao and Bangladeshi versions of generic drugs, and the price is around two to three thousand. It is worth noting that the ingredients of original drugs and generic drugs are basically the same.